Treating Alzheimer's disease in a person living with HIV

INTRODUCTION: Human immunodeficiency virus (HIV) therapies now support survival into advanced ages by suppressing HIV replication and preserving immune function. Alzheimer's disease (AD), the most common neurologic degenerative condition, may now be treated with anti-amyloid therapies (AAT). HIV was an exclusionary criterion in clinical trials for AAT, leaving the safety and efficacy of these medications unknown in this setting. METHODS: We report the development of AD supported by careful evaluations and biomarkers over a 10-year period in a person living with well-controlled HIV infection. RESULTS: AD was diagnosed with consistent clinical and biomarker evidence. AAT was successfully administered without complications. HIV therapy remained effective. DISCUSSION: This report provides early evidence that AAT can be safely administered without detrimental effects on HIV therapy. The rapidly enlarging elderly HIV population will include an increasing number of individuals with AD who may benefit from this knowledge.